1 / 1

ACE-I & ARB’s are beneficial in normotensive atherosclerotic patients

ACE-I & ARB’s are beneficial in normotensive atherosclerotic patients. a collaborative meta-analysis of randomized trials. 13 trials of 80,594 patients; outcomes included 5674 CV deaths, 3106 MIs, and 4452 strokes .

osias
Download Presentation

ACE-I & ARB’s are beneficial in normotensive atherosclerotic patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACE-I & ARB’s are beneficial in normotensive atherosclerotic patients a collaborative meta-analysis of randomized trials • 13 trials of 80,594 patients; outcomes included 5674 CV deaths, 3106 MIs, and 4452 strokes. • ACE-I or ARB reduced these by 11% (95% CI 7–15%), with no variation in efficacy across baseline BP strata. • In patients with baseline SBP <130 mmHg, ACE-I or ARB reduced the composite primary outcome by 16% (10–23%) McAlister FA et al, EurHeart J. 2011 Oct 31

More Related